Last update:
Clinical pharmacology news
Oral GLP-1s without fasting or reduced efficacy: Delivery approach protects peptide-based drugs from stomach acid
Biomedical engineers at Duke University have developed a new approach to delivering GLP-1 medications orally that does not require fasting and maintains their efficacy. The technique could also be useful for any pharmaceutical ...
54 minutes ago
0
0
How different SSRIs affect metabolism in early brain development
A new study from Karolinska Institutet shows that different SSRI medications affect metabolic processes in developing nerve cells in distinct ways. Alterations in energy metabolism, oxidative stress and lipid profiles suggest ...
2 hours ago
0
1
Race to find vaccines, treatments for Ebola strain behind outbreak
An escalating outbreak of a rare Ebola strain in the Democratic Republic of Congo has kicked off a race to find vaccines and treatments that can be quickly tested and rolled out to save lives and stem the crisis.
5 hours ago
0
1
Which patients benefit most from tirzepatide GLP-1 for obesity and obstructive sleep apnea?
Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally. Now, new research presented at the 2026 ATS International ...
8 hours ago
0
4
New research finds low-dose buprenorphine may help sustain ketamine's benefits for suicidal ideation
New research published in the American Journal of Psychiatry finds that low-dose buprenorphine, given after a single ketamine infusion, significantly sustained reductions in suicidal ideation in adults with major depressive ...
11 hours ago
0
3
Creatine improves physical performance but does not necessarily reduce inflammation, finds study
Creatine, one of the most popular supplements among gym-goers and athletes, does not appear to have the anti-inflammatory effect that many imagine. This conclusion comes from a systematic review and meta-analysis conducted ...
23 hours ago
0
4
FDA approves label expansion for Vyvgart, Vyvgart Hytrulo for generalized myasthenia gravis
The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with (gMG). The ...
22 hours ago
0
4
At 'most favored nation' prices, can Medicare break even on GLP-1 drugs?
In November 2025, the White House announced pricing deals with multiple pharmaceutical manufacturers to lower domestic prices for glucagon-like peptide-1 receptor agonist drugs (GLP-1RAs) including Ozempic, Wegovy, Mounjaro, ...
May 18, 2026
0
6
Statistical method may overstate Alzheimer's drugs' cognitive benefits by 29 times
A statistical approach being used to support a new class of Alzheimer's drugs may lead to overstated claims about how the drugs work, according to a new study led by researchers at the Brown University School of Public Health.
May 18, 2026
0
12
New drug target identified for Fragile X syndrome
UCLA Health researchers have identified a potential drug target for treating Fragile X syndrome, the most common genetic cause of intellectual disability and autism that affects roughly one in 2,000 boys.
May 18, 2026
0
5
Why an off-label autism drug suddenly took off, despite limited large-scale evidence
Researchers from the University of California San Diego found that prescriptions for leucovorin, a drug sometimes used off-label for autism spectrum disorder (ASD), rose sharply among children after widespread media attention ...
May 18, 2026
0
4
Automation cuts prostate cancer drug candidate production from 6 hours to 38 minutes
A proof-of-concept study has created a blueprint for producing prostate cancer treatment more efficiently. Researchers at the University of Missouri, Cancer Targeted Technology (CTT) and Isotherapeutics Group (ITG) discovered ...
May 18, 2026
0
6
Scientists develop first-in-class drug candidate for chronic itch
Chronic itch is often described as an "invisible torment." It can persist for weeks or months, severely affecting sleep, mental health, and quality of life. In patients with cholestatic liver disease, chronic itch remains ...
May 18, 2026
0
2
Clinical trial shows tezepelumab controls asthma in diverse patient population
The drug tezepelumab was shown to significantly reduce exacerbations in people with severe asthma in clinical trials. Now, a new study presented at the 2026 ATS International Conference shows that it is also safe and effective ...
May 18, 2026
0
6
Japan pharmaceutical firm warns against rare diseases drug after deaths
A Japanese pharmaceutical firm has warned doctors against prescribing a drug for rare autoimmune diseases to new patients following the deaths of 20 people who took it.
May 16, 2026
0
12
FDA official who scrutinized COVID shots and antidepressants is out in latest shake-up
A Food and Drug Administration official involved in scrutinizing the safety of antidepressants, COVID-19 vaccines and other widely used therapies has been removed from her role leading the agency's drug program.
May 16, 2026
0
7
New targeted radiopharmaceutical therapy induces remission in pancreatic cancer model
A newly developed targeted radiopharmaceutical treatment can effectively slow tumor growth in pancreatic ductal adenocarcinoma (PDAC), according to new research published in the May issue of The Journal of Nuclear Medicine. ...
May 15, 2026
0
80
Single dose of psilocybin provides rapid relief from depression in double-blind study
A single dose of the psychedelic substance psilocybin can provide rapid relief from depressive symptoms—within just a few days. This is shown by the first randomized, double-blind study in Sweden of psilocybin for depression. ...
May 15, 2026
0
51
ADHD medications show dosage sweet spots, with little gain above limits
Researchers have identified the best dosage for each ADHD medication using data from thousands of people with the condition. The new study published in The Lancet Psychiatry provides the most comprehensive view of dosage ...
May 15, 2026
0
37
Antiviral ensitrelvir cuts risk of COVID-19 in household contacts by two-thirds, study finds
The antiviral drug ensitrelvir prevents infection in household contacts of COVID-19 patients when given within 72 hours after symptom onset in the index patient, according to a Phase III randomized controlled trial published ...
May 15, 2026
0
19
Improving the treatment of Lassa fever: First clinical trial with favipiravir shows promising results
The infectious disease Lassa fever can be fatal, and there is a lack of treatment options with proven efficacy. Researchers at the Bernhard Nocht Institute for Tropical Medicine (BNITM) and the University Medical Center Hamburg-Eppendorf ...
May 15, 2026
0
4
New obesity guidance urges dietitian-led care as GLP-1 drugs reshape treatment
Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding the use of obesity drugs for weight loss treatment. The consensus statement was presented at the European ...
May 15, 2026
0
7
Study links use of new obesity drugs to reduction of asthma exacerbations and inhaler use
New research presented at the European Congress on Obesity in Istanbul, Turkey (May 12–15) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26% fall in the number of asthma ...
May 15, 2026
0
5
Wegovy initiation may cut migraine drug use 8% in women after one year
A nationwide study from Denmark presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey, shows that use of semaglutide (Wegovy) for weight management is associated with a 7% reduction in the use of triptan-class ...
May 15, 2026
0
4
Researchers explore making behavioral health care more accessible
A study published in the American Journal of Managed Care explores how integrating behavioral health care into primary care can improve outcomes and be cost-effective for adults with depression, anxiety and chronic pain who ...
May 15, 2026
0
3
